This week: the FDA accepts NDA for investigational antibiotic; mRNA COVID-19 vaccines update protections; counseling families on nirsevimab; and how antibiotic actions on gut microbes of patients might affect the microbiome of housemates.
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
The latest CDC numbers show a 6.2% increase of measles cases from week-to-week. Last week there was a 5.4% increase in cases showing a continuing steady increase dictated by ongoing outbreaks across the US.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
IDSA/ESCMID panel member Henry Chambers, MD, explains why the new S aureus bacteremia guidance replaces the complicated vs uncomplicated label with risk stratification, and how the statements are akin to the stages of cancer in guiding treatment decisions associated with this bacteremia.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
Following World Rabies Day and a CDC health advisory on a 17% rise in exposure-related calls, Rodney E. Rohde, PhD, explains what the increase means, what people should do when they have an animal bite or scratch, and how clinicians should assess risk and administer post-exposure prophylaxis (PEP).
